Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...
The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...
William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...
Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors ...
Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback